Irish Coalition for People Living with Obesity's Susie Birney did say however, that many people in Ireland have seen their ...
Losing weight can be a challenge for many. With so many variables present in everyday life, including stress, lack of sleep, ...
The company also raised its quarterly dividend 15% amid rapid growth fueled in part by the blockbuster weight-loss drug ...
People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...
They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...
With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions ...
Prescriptions for weight-loss drugs surged in 2024 and were much more popular in some states, particularly those in the South ...
Weight-loss injection Mounjaro, also known as tirzepatide, will be rolled out on the NHS gradually over a 12-year period.
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.
It's what most investors want more than anything else from their stocks. Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December.